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ABSTRACT 
Even though cultural, biological and health service factors influence the tolerance and 
acceptability of psychoUopic drugs in different settings, there is a lack of data on the use of 
antidepressants in primary care settings from India. The aim of this study was to examine the 
tolerance of 3 models of antidepressants treatments (fluoxetine 20 mg; imipramine 75 mg; imipramine 
150 mg) for commoh mental disorders in attenders at a primary care clinic in Goa. The study design 
was a randomized trial. A total of€1 adult subjects with a common mental disorder were recruited 
and randomized to one of the 3 groups. Subjects were reviewed at 2 and 6 weeks. The main 
outcome measures were discontinuation rates. The key findings are that while discontinuation rates 
are higher in subjects on imipramine 150 mg as compared to the other groups, the majority of 
subjects in all groups discontinued their medication. The commonest reasons for discontinuation 
are anticholingeric and hypotensive side effects. 
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Common Mental Disorders (CMD) are 
disorders characterised by the presentation of 
nonspecific, multiple somatic symptoms, sleep 
disturbances and psychological symptoms of 
anxiety and depression. CMD are amongst the 
most frequent and most disabling of all disorders 
encountered in primary care (Ormel et al.,1994). 
Psychiatric morbidity can be detected in up to 
half of adult PHC attenders in India (Shamasundar 
et al.,1986; Sen,1987). CMD accounts for most 
of this morbidity, up to two-thirds of which is 
unrecognized and either untreated to treated with 
inappropriate medication. This sub-optimal 
management leads to persisting symptoms, 
excess health service use and loss working ability 
(Pateletal.,1998a; 1998c). 
The aim of the trial described in this paper 
was to compare the tolerance and side-effects 
profile of patients attending primary health clinics 
[PHC] with a CMD, comparing 3 groups: 
imipramine 150 mg which was the dose 
recommended by psychiatric textbooks; 
trial, discontinuation rates 
imipramine 75 mg which is the maximum dose, 
generally prescribed by private practitioners; and 
fluoxetine 20 mg which is rarely prescribed in 
primary care due to the perceived higher costs. 
The specific objectives of the trial were to 
address the following questions : 
1) Which group of anti-depressant therapy is 
more acceptable in terms of side effects profile 
and patient compliance as estimated by side 
effect checklists and discontinuation rates ? 
2) This study is, to the best our knowledge, the 
first double blind randomized trial of 
antidepressants in primary care in India. Thus, the 
study was designed as a pilot trial with the aim of 
identifying the antidepressant of choice for a 
definitive trial in general health care and to 
determine the feasibility of large trials in this setting. 
MATERIAL AND METHOD 
Site : Peri urban PHC in the state of Goa on the 
west coast of India. 
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Population : Outpatient attenders. 
Sample Selection : This is outlined in figure 1. 
Recruitment Procedure : A standard two stage 
process of selecting subjects with CMD was 
employed. The 5 item Konkani GHQ was used 
as a screening questionnaire and the Revised 
Clinical Interview Schedule as a second stage 
diagnostic interview for CMD. The CISR is a 
structured interview for the measurement of CMD 
in community and primary care settings (Lewis et 
al.,1992). Details of the translation and use of the 
Konkani versions of the CISR and the validation 
of the GHQ-5 in an earlier study in primary care 
are published elsewhere (Patel et al., 1998b). 
Written Informed Consent : Written informed 
consent provided information advising the subject 
about the blind nature of the treatment, potential 
side-effects and the freedom to drop-out if they 
wished before the completion of the trial. 
Sample Size & Randomization : A sample of 61 
out patient attenders were recruited on the basis 
of the steps outlined in figure 1. Power calculations 
were not undertaken because of the unknown level 
of expected drop-out rates for the different drug 
groups and due to the pilot nature of the trial. 
Subjects were then randomized to any of 3 
treatment groups based on an allocation schedule 
generated by a simple randomization table. 
Randomization Groups : 
1. (mipramine 75 mg : this group received 50 
mg for 1 week which was increased to 75 mg 
afterwards. All medication was taken at bedtime. 
2. Imipramine 150 mg : this group received 50 
mg for 1 week, 75 mg in the second week and 
150 mg thereafter. All medication was taken at 
bedtime. 
3. Fluoxetine : this group received 20 mg in the 
morning daily throughout. 
Blinding : All the patients were ultimately 
receiving the drugs in a capsule form in sealed 
packets at recruitment (2 week supply) and at 
two week follow up (4 week supply). The 
allocation schedule regarding the type of 
medication and randomization of patients in the 
trial which were held by the first author were 
broken only when the trial was completed. The 
interviews were carried out by two investigators 
who were blind as to what treatment the patients 
were receiving. 
Outcome Assessments : Patients were 
assessed at 2 weeks and 6 weeks after 
recruitment. Subjects who failed to take 75% of 
the medication in the period prior to review were 
considered to have been noncompliant 
(discontinuation rate). Subjects who discontinued 
were asked open questions about the reasons 
for noncomplying. 
Analysis : Drop-out rates were compared 
between the 3 groups using odds ratios. 
FIGURE 1 
FLOW CHART OF ANTIDEPRESSANT TRIAL 
Score 2 or less Score 3 or more 
1 1 
Exclude Revised Clinical Interview Schedule 
Score 11 or less Score 12 or more 
1 1 
Exclude Written Informed Consent 
I 
RANDOMIZATION 
I I 1 
IMIPRAMINE 75 mg IMIPRAMINE 150 mg FLUOXETINE 20mg . 
I 
2 WEEK REVIEW: 
Side effect Checklist 
I 
6 WEEK REVIEW: 
Side effect Checklist 
RESULT 
The Sample : A total of 61 subjects were 
recruited. The mean age was 46.5 years (sd 10.75 
range 25-60 years). Females constituted about 
Consecutive PHC attenders 
INCLUSION CRITERIA: 
1. Age 20-60 years 
2. Konkani or English speaking 
3. Lives in Santa Cruz 
EXCLUSION CRITERIA: 
1 .Acute medical/psychiatric needing urgent intervention. 
2.Prostatic hypertrophy, glaucoma,IHD, deafness, pregnane) 
3.Already on any psychotropic medication 
Interview with GHQ6 
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97% of the total while only 3% were males. 
Majority of the patients (77%) had not completed 
school, while 23% had finished their SSC. 59% 
of the patients were married while 39% patients 
were widowed. 80% of the patients were 
unemployed while only 13% were engaged in 
skilled labor. Catholics constituted 59% while 
38% were Hindus. The mean CISR scores was 
25 (sd 8; Range : 12-43). Of the 61 subjects, 58 
were traced for interview at 2 and 6 weeks 
providing a follow-up rate of over 95%. 
Adequacy of Randomization : 21 subjects 
received fluoxetine, 20 received imipramine 75 
mg and 20 received imipramine 150 mg. All three 
treatment groups were well matched after 
randomization with respect to age (p=0.52); 
CISR scores at recruitment (p=0.69) and gender. 
Diagnostic Categories : The commonest ICD-
10 diagnoses were those of depressive disorder 
and mixed anxiety depressive disorder (table 1). 
TABLE 1 
ICD-10 DIAGNOSTIC CATEGORIES OF SUBJECTS 
IN THE TRIAL 
ICD-10 
Mild depressive episode 
Moderate depressice episode 
Severe depressive episode without 
psychotic symtoms 
Panic disorder 
Mixed Anxiety and Depressive disorder 
Nerurasthenia 
No. 
7 
16 
11 
2 
23 
2 
% 
15 
33 
23 
4 
38 
4 
Discontinuation Rates and Side-effects : 
Discontinuation rates for the 3 groups at 2 and 6 
weeks follow-up are presented in table 2. The 
TABLE 2 
OUTCOME OF DISCONTINUATION AND COMPLETION RATES 
main finding was that the highest proportion of 
treatment completers was in the fluoxetine 
group. However, even in this group, the majority 
of subjects did not complete the medication 
regime. There was no significant difference in 
discontinuation rates between fluoxetine and 
imipramine 75 mg. However, subjects in the 
imipramine 150 mg group were more likely to 
discontinue when compared to subjects in the 
other two groups combined. Thus, at 2 weeks, 
the odds for a subject on imipramine 150 mg to 
discontinue was 2.8 (95% CI 0.7-11.1) and at 6 
weeks it was 2.3 (95% CI 0.5-12.2). Out of the 
40 patients from the original sample who did not 
complete the trial 33 patients (82.5%) 
discontinued due to side effects of medication. 
The commonest side effects seen at 2 weeks 
were palpitations, giddiness, blurring of vision, 
dryness of mouth, drowsiness, restlessness, 
confusion and headache. While anticholinergic 
side effects and giddiness (possibly related to 
postural hypotension) were common in the 
imipramine groups, headaches and restlessness 
were common in the fluoxetine group. 
Predictors of Outcome Based On 
Recruitment Variables : The greater the age of 
the person, more were the odds of completing 
the trial (OR=1.1, 95% CN1-1.19, p=0.015). 
Religion was the other factor with the odds greater 
for Catholics completing the trial (OR=3.6, 95% 
Cl=0.9-14.7, p=0.06). Recruitment CISR score, 
occupation, marital status and qualification were 
not related to drop-out rates. 
Drug Type 
Fluoxetine 
Imipramine 
75 mg 
Imipramine 
150mg 
Total 
N 
% 
N 
% 
N 
% 
N 
% 
FT 
7 
33.3% 
5 
25% 
3 
15% 
15 
29.5% 
D02 
8 
38.1% 
11 
55% 
14 
70% 
33 
54.10% 
D06 
4 
19.05% 
4 
20% 
2 
10% 
10 
16.3% 
Unknown/Lost 
2 
9.5% 
0 
1 
5% 
3 
4.9% 
Total 
21 
20 
20 
61 
FT=Completed trial, i.e. took>75% medication for full duration of trial 
D02= Discontinued between recruitment and followup at 2 weeks 
D06=Discontinued between followup at 2 weeks and followup at 6 weeks 
360 ANTIDEPRESSANT TRIAL IN PRIMARY CARE 
DISCUSSION 
There is a growing literature on the 
effectiveness of antidepressant and psychological 
interventions for CMD from developed societies 
(Paykel & Priest, 1992). Given the varying nature 
of the health systems and cultures in low-income 
countries, it is necessary to evaluate the 
effectiveness of treatments for CMD in these 
settings. An example of this variability is the cost 
of drugs in different health systems. Thus, SSRIs 
cost substantially more than older tricyclics in 
developed countries leading to a recommendation 
to use the latter inspite of the higher risk of side-
effects and drop-outs (Hotopf et al.,1996 & 1997). 
However, due to the deregulation of the 
pharmaceutical industry in India, SSRIs such as 
fluoxetine in therapeutic doses have a comparable 
cost to older tricyclics and are cheaper than the 
newer tricyclics (Patel, 1996). Similarly, anecdotal 
and clinical evidence from India and other low-
income settings suggest the therapeutically 
effective dose of tricyclic anti-depressants is lower 
than that recommended for European patients 
(Kilonzo et al.,1994). To the best of the knowledge 
of the authors, derived from a review of recent 
metanalyses of trials for CMD and depression 
(Song et al.,1993; Hotopf et al.,1996) there are 
no published trials of the treatment of CMD in 
PHC attenders in low-income countries. 
There have been very few studies on the 
use of antidepressants for CMD in India; those 
that have been published, such as the study by 
Singh & Sharma (1987), have used psychiatric 
outpatient samples. It is well recognized that the 
vast majority of patients with CMD only consult 
in primary care settings and findings from 
psychiatric settings may not be applicable to 
primary care. To date, there are no published 
randomized trials comparing the acceptability, 
efficacy and cost of low dose tricyclic, full-dose 
tricyclic and SSRI antidepressants in primary 
care settings in India. The overall aims of the 
study described in this paper were twofold : first, 
to establish whether there was any difference in 
tolerance between 3 widely used models of 
antidepressant treatments in primary care so that 
a choice could be made for a more subsantive 
trial evaluating efficacy in the future. Second, to 
examine the feasibility of conducting randomized 
trials of psychiatric treatments in primary care 
settings in India. The major limitation of this study 
is the small sample sizes in the 3 groups. This 
limitation must be taken into account when 
interpreting the finding of trends which are 
statistically non-significant but could be 
significant had the sample sizes been larger. It 
is our belief, given the significantly higher non-
completion rates for the imipramine 150 group, 
that the trends would have been statistically 
significant were the samples larger. The second 
limitations is that discontinuation rates were so 
high that an intention to treat analysis for 
examining the difference in efficacy between the 
3 groups was not feasible. All these limitations 
must however be considered in the light of the 
fact that this was a pilot study and that many of 
the limitations are in fact feasibility issues which 
will inform future trials. 
The main findings of the trial are, first, 
that irrespective of the type or dose of 
antidepressant and despite the fact that the 
medication was' free and considerable 
explanation was given to subjects as part of the 
informed consent procedure, discontinuation 
rates were high. Second, there was a higher 
discontinuation rate in the imipramine 150 mg 
group, mostly attributable to adverse effects of 
the drug. The commonest adverse effects which 
led to discontinuation were anticholinergic side 
effects and postural hypotension leading to 
giddiness. Thus, it is our view that the full dose 
of imipramine has limited value in general health 
care settings. There was no significant difference 
between imipramine 75 mg and fluoxetine 20 
mg in terms of tolerance and discontinuation. It 
was noted that the discontinuation rates at 2 
weeks were higher for the imipramine 150 mg 
group as compared to the imipramine 75 mg 
group even though, at this point in the trial, 
subjects in both groups were receiving the same 
dose of imipramine (50 mg). One possible 
361 JERSON PEREIRA & VIKRAM PATEL 
explanation for this apparent discrepancy is that 
subjects in the 75 mg group felt that they had 
already reached the maximum dose possible and 
were more accepting of the side effects they had 
experienced, whereas those who were in the 150 
mg group were apprehensive that the expected 
increase in dosage would exacerbate their side 
effects. Given the fact that the commonest 
interventions currently used in general health 
care settings, viz., vitamins and other 
symptomaic treatments, are often considered to 
be "placebo" medicines, it would be of 
considerable interest to examine whether 
antidepressants are superior to these 
medications in a controlled trial. In particular, it 
would be of interest to compare discontinuation 
rates between drug and placebo. Thus, there is 
a need to conduct a substantive randomized 
placebo-controlled trial to examine the efficacy 
and cost-effectiveness of either fluoxetine 20 mg 
or imipramine 75 mg in primary or general health 
care settings. 
In terms of the second objective of the 
trial, i.e. feasibility issues relating to randomized 
controlled trials, it is clear that the high 
discontinuation rates in all 3 groups due to side 
effects poses a major challenge to trials with 
antidepressants in general health care settings. 
Future trials will need to concentrate on 
improving compliance rates using sensitive 
education of patients regarding side effects, 
adequate monitoring using home visits and other 
forms of reminders as feasible and using drugs 
with the least side effects. The high 
discontinuation rates also challenges the notion 
that most primary care patients in India are 
prepared to take metiication in preference to 
other options such as psychological treatments 
(though, to our knowledge, there have been no 
comparisons of these treatments in India). Thus, 
there is also a need to compare the acceptability 
and cost-effectiveness of pharmacological and 
psychological interventions in general health 
care. The second author is currently conducting 
a definitive placebo-controlled trial of 
antidepressant (fluoxetine chosen as a result of 
this pilot trial) and psychological treatment for 
comparison of efficacy and cost-effectiveness 
in general health care. Many of the lessons 
learned from this pilot trial are being used to 
attempt to improve compliance rates with 
treatments. The findings of that trial will be 
published in due course. 
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